ClinicalTrials.gg
TerminatedNCT01467479Updated Mar 17, 2015Results posted

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

A Phase 3 interventional study of Telaprevir and Ribavirin in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 59 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-17.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Why this study was terminated
It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.

Enrollment
8th of 39
185 · median 30
Started
2011
with 3 others
Phase 3
13 of 39
none open now
Registered
21st of 39
by date
Lead sponsor
12 of 39
Vertex Pharmaceuticals Incorporated

Among the 39 studies testing telaprevir in Hepatitis C, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 21st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing telaprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have chronic, genotype 1a or 1b, with HCV RNA greater than (>) 1000 international units per milliliter (IU/mL)
  • Population A: HCV Pegylated interferon (Peg-IFN)/RBV treatment naive (received no prior HCV therapy)or Peg-IFN/RBV prior treatment with relapse
  • Population B: Peg-IFN/RBV prior null or partial responder
  • Participants must not have achieved undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24) after at least 1 prior course of Peg IFN/RBV therapy of standard duration
  • Participant must have positive antibody at Screening
  • Participant must have a diagnosis of HIV-1 infection >6 months before Screening
  • Participants should be taking 1 of the following permissible highly active antiretroviral therapy (HAART) regimens for HIV continuously for 12 weeks prior to screening:

    • Atripla® or equivalent components (efavirenz, tenofovir, emtricitabine)
    • Efavirenz plus Epzicom® (abacavir, lamivudine) or equivalent components
    • Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir, emtricitabine) or equivalent components
    • Boosted atazanavir plus Epzicom®, or equivalent components
    • Raltegravir plus Truvada®, or equivalent components
    • Raltegravir plus Epzicom®, or equivalent components
  • Cluster of differentiation 4 (CD4) counts and human immunodeficiency virus Type 1 (HIV-1) ribonucleic acid (RNA) meeting acceptable criteria at Screening as specified in the protocol
  • Laboratory values within acceptable ranges at Screening as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Subjects anticipating a need to switch HAART regimens within 14 weeks after Day 1 or any switches occurring 12 weeks prior to Day 1
  • Use of azidothymidine (AZT), didanosine (ddI) or stavudine (d4T) nucleosides
  • to any planned HAART component as per the respective drug labeling information
  • Contraindications to Peg-IFN or RBV
  • Evidence of hepatic decompensation
  • Clinical suspicion of acute hepatitis
  • Any other cause of liver disease in addition to
  • History of organ transplantation (except cornea and skin)
  • -mediated disease
  • Participated in any drug study within 90 days before Day 1
  • Previous treatment with an HCV protease inhibitor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    T/PR + HAART Regimen (ATV/r-Based)

    Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.

    Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)

  • Experimental
    T/PR + HAART Regimen (EFV-Based)

    Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.

    Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)

  • Experimental
    T/PR + HAART Regimen (RAL-Based)

    Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.

    Drug: Telaprevir · Drug: Ribavirin · Biological: Pegylated Interferon Alfa-2a · Drug: Highly Active Antiretroviral Therapy (HAART)

Interventions

  • Tablet

    Also known as: VX-950

  • Tablet

    Also known as: Copegus®, RBV

  • Subcutaneous Injection

    Also known as: Pegasys®, Peg-IFN-Alfa-2a

  • DrugHighly Active Antiretroviral Therapy (HAART)

    Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

    SVR 12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma hepatitis C virus ribonucleic acid (HCV RNA) level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

    Time frame: 12 weeks after last planned dose of study drug (up to Week 60)

Secondary outcomes

  1. Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)

    SVR 24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

    Time frame: 24 weeks after last planned dose of study drug (up to Week 72)

  2. Percentage of Participants With Rapid Viral Response (RVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. RVR was defined as undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.

    Time frame: Week 4

  3. Percentage of Participants With Extended Rapid Viral Response (eRVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

    Time frame: Week 4 and Week 12

  4. Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Percentage of participants with undetectable HCV RNA (\<lower limit of quantification) at EOT (up to Week 48) are reported. Data for this outcome was not planned to be reported by prior response.

    Time frame: EOT (up to Week 48)

  5. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: Up to Week 52

  6. Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)

    Cmax, Cmin, and Cavg were reported for atazanavir (ATV), efavirenz (EFV), raltegravir (RAL), and telaprevir.

    Time frame: Day -14 to Day -1 and Week 1 for ATV, EFV, and RAL; Week 1 for telaprevir

  7. Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

    Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by HAART treatment.

    Time frame: Baseline, follow-up (Week 96)

07

Results

Posted Mar 17, 2015
Limitations and caveats
It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.

Participant flow

Study included Treatment-Naïve (no prior hepatitis C virus \[HCV\] therapy); Prior Relapser (prior HCV treatment with pegylated interferon alfa/ribavirin \[Peg-IFN/RBV\] and experienced viral relapse); and Prior Null/Partial Responder (prior HCV treatment with Peg-IFN/RBV and had null/partial response) participants.

Participant flow — Overall Study
MilestoneT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Started556961
Treated546959
Completed465245
Not completed91716
Withdrew: No study medication102
Withdrew: Adverse event120
Withdrew: Death001
Withdrew: Lost to follow-up253
Withdrew: Withdrawal of consent377
Withdrew: Study terminated by sponsor133
Withdrew: Other100

Outcome measures

PrimaryPercentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

SVR 12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma hepatitis C virus ribonucleic acid (HCV RNA) level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

Time frame:
12 weeks after last planned dose of study drug (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Treatment Naïve (n= 24, 39, 31)66.759.061.3
Prior Relapser (n=8, 11, 4)75.054.5100
Prior Null Responder (n= 15, 11, 15)4036.440
Prior Partial Responder (n= 7, 8, 9)14.387.555.6
Total (n= 54, 69, 59)53.758.057.6
SecondaryPercentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)

SVR 24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (\<lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL).

Time frame:
24 weeks after last planned dose of study drug (up to Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Treatment Naïve (n= 23, 38, 29)65.257.951.7
Prior Relapser (n=8, 11, 4)75.054.5100
Prior Null Responder (n= 15, 9, 14)33.322.235.7
Prior Partial Responder (n= 7, 8, 9)14.375.055.6
Total (n= 53, 66, 56)50.954.551.8
SecondaryPercentage of Participants With Rapid Viral Response (RVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. RVR was defined as undetectable HCV RNA (\<lower limit of quantification) 4 weeks after the start of study treatment.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Rapid Viral Response (RVR)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Treatment Naïve (n= 24, 39, 31)50.053.874.2
Prior Relapser (n=8, 11, 4)62.572.7100
Prior Null Responder (n= 15, 11, 15)26.754.553.3
Prior Partial Responder (n= 7, 8, 9)42.950.044.4
Total (n= 54, 69, 59)44.456.566.1
SecondaryPercentage of Participants With Extended Rapid Viral Response (eRVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. eRVR was defined as undetectable HCV RNA (\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Extended Rapid Viral Response (eRVR)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Treatment Naïve (n= 24, 39, 31)50.053.861.3
Prior Relapser (n=8, 11, 4)62.572.7100
Prior Null Responder (n= 15, 11, 15)26.754.553.3
Prior Partial Responder (n= 7, 8, 9)14.350.044.4
Total (n= 54, 69, 59)40.756.559.3
SecondaryPercentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL. Percentage of participants with undetectable HCV RNA (\<lower limit of quantification) at EOT (up to Week 48) are reported. Data for this outcome was not planned to be reported by prior response.

Time frame:
EOT (up to Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)55.663.861.0
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
AEs10095.794.9
SAEs13.011.615.3
SecondaryMaximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)

Cmax, Cmin, and Cavg were reported for atazanavir (ATV), efavirenz (EFV), raltegravir (RAL), and telaprevir.

Time frame:
Day -14 to Day -1 and Week 1 for ATV, EFV, and RAL; Week 1 for telaprevir
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)
nanogram per milliliter (ng/mL)T/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
ATV: Day -14 to Day -1, Cmax(n=46, 0, 0)2870 ± 1580NA ± NANA ± NA
ATV: Day -14 to Day -1, Cmin(n=46, 0, 0)991 ± 635NA ± NANA ± NA
ATV: Day -14 to Day -1, Cavg(n=41, 0, 0)1100 ± 647NA ± NANA ± NA
ATV: Week 1, Cmax (n=42, 0, 0)2820 ± 1570NA ± NANA ± NA
ATV: Week 1, Cmin (n=42, 0, 0)1280 ± 636NA ± NANA ± NA
ATV: Week 1, Cavg (n=30, 0, 0)1320 ± 685NA ± NANA ± NA
EFV: Day -14 to Day -1, Cmax(n=0, 60, 0)NA ± NA3800 ± 2600NA ± NA
EFV: Day -14 to Day -1, Cmin(n=0, 60, 0)NA ± NA2560 ± 1900NA ± NA
EFV: Day -14 to Day -1, Cavg(n=0, 51, 0)NA ± NA2150 ± 1680NA ± NA
EFV: Week 1, Cmax (n=0, 51, 0)NA ± NA3340 ± 2450NA ± NA
EFV: Week 1, Cmin (n=0, 51, 0)NA ± NA2290 ± 1880NA ± NA
EFV: Week 1, Cavg (n=0, 47, 0)NA ± NA1920 ± 1400NA ± NA
RAL: Day -14 to Day -1, Cmax(n=0, 0, 52)NA ± NANA ± NA1900 ± 1880
RAL: Day -14 to Day -1, Cmin(n=0, 0, 52)NA ± NANA ± NA196 ± 198
RAL: Day -14 to Day -1, Cavg(n=0, 0, 35)NA ± NANA ± NA483 ± 429
RAL: Week 1, Cmax (n=0, 0, 49)NA ± NANA ± NA2320 ± 1970
RAL: Week 1, Cmin (n=0, 0, 49)NA ± NANA ± NA281 ± 435
RAL: Week 1, Cavg (n=0, 0, 34)NA ± NANA ± NA643 ± 539
Telaprevir: Week 1, Cmax(n=49, 59, 54)3160 ± 11803780 ± 16703470 ± 868
Telaprevir: Week 1, Cmin(n=49, 59, 54)1650 ± 8631750 ± 9611840 ± 741
Telaprevir: Week 1, Cavg(n=30, 32, 26)2320 ± 9072430 ± 12902520 ± 643
SecondaryNumber of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region

Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by HAART treatment.

Time frame:
Baseline, follow-up (Week 96)
Reported as:
Number · participants
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
participantsT/PR + HAART Regimen
Baseline (n = 180)2
Follow-up (n = 26)11

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T/PR + HAART Regimen (ATV/r-Based)—7/54 (13%)54/54 (100%)
T/PR + HAART Regimen (EFV-Based)—8/69 (11.6%)66/69 (95.7%)
T/PR + HAART Regimen (RAL-Based)—9/59 (15.3%)56/59 (94.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
AnaemiaBlood and lymphatic system disorders0/543/694/59
NeutropeniaBlood and lymphatic system disorders1/541/691/59
LeukocytosisBlood and lymphatic system disorders1/540/690/59
VomitingGastrointestinal disorders1/540/690/59
Escherichia urinary tract infectionInfections and infestations1/540/690/59
Psoas abscessInfections and infestations1/540/690/59
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders1/540/690/59
PneumonitisRespiratory, thoracic and mediastinal disorders1/540/690/59
Non-cardiac chest painGeneral disorders1/540/690/59
Flank painMusculoskeletal and connective tissue disorders1/540/690/59
Most frequent other events
Showing 10 of 351
Most frequent other events
EventT/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)
FatigueGeneral disorders26/5436/6930/59
NauseaGastrointestinal disorders23/5422/6919/59
PruritusSkin and subcutaneous tissue disorders22/5421/6918/59
HeadacheNervous system disorders15/5417/6920/59
DiarrhoeaGastrointestinal disorders13/5421/696/59
AnaemiaBlood and lymphatic system disorders15/5421/6916/59
RashSkin and subcutaneous tissue disorders16/5420/6911/59
InsomniaPsychiatric disorders9/5414/6914/59
NeutropeniaBlood and lymphatic system disorders10/5415/694/59
VomitingGastrointestinal disorders10/5411/6911/59

Baseline characteristics

The Full Analysis Set (FAS), included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)T/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)Total
Mean50.4 ± 8.8149.6 ± 8.8448.4 ± 9.5849.5 ± 9.06
Sex: Female, Male
Sex: Female, Male(Participants)T/PR + HAART Regimen (ATV/r-Based)T/PR + HAART Regimen (EFV-Based)T/PR + HAART Regimen (RAL-Based)Total
Female691530
Male486044152
08

Study locations

59 sites
  • Alabama
    Birmingham, Alabama, United States
  • California
    Bakersfield, California, United States
  • California
    Beverly Hills, California, United States
  • California
    Coronado, California, United States
  • California
    Los Angeles, California, United States
  • California
    Oakland, California, United States
  • California
    Palo Alto, California, United States
  • California
    Sacremento, California, United States
  • California
    San Diego, California, United States
  • California
    San Francisco, California, United States
  • Connecticut
    New Haven, Connecticut, United States
  • DC
    Washington DC, District of Columbia, United States
  • Washington, DC
    Washington, District of Columbia, United States
  • Florida
    Bay Pines, Florida, United States
  • Florida
    Jacksonville, Florida, United States
  • Florida
    Miami, Florida, United States
  • Florida
    Orlando, Florida, United States
  • Florida
    West Palm Beach, Florida, United States
  • Georgia
    Atlanta, Georgia, United States
  • Georgia
    Decatur, Georgia, United States
  • Illinois
    Chicago, Illinois, United States
  • Maine
    Portland, Maine, United States
  • Maryland
    Baltimore, Maryland, United States
  • Maryland
    Lutherville, Maryland, United States
  • Massachusetts
    Springfield, Massachusetts, United States
  • Michigan
    Detroit, Michigan, United States
  • Minnesota
    Minneapolis, Minnesota, United States
  • Missouri
    Kansas City, Missouri, United States
  • Missouri
    Saint Louis, Missouri, United States
  • New Jersey
    Newark, New Jersey, United States
  • New Mexico
    Santa Fe, New Mexico, United States
  • New York
    Bronx, New York, United States
  • New York
    New York, New York, United States
  • New York
    Rochester, New York, United States
  • North Carolina
    Durham, North Carolina, United States
  • Ohio
    Cincinnati, Ohio, United States
  • Ohio
    Cleveland, Ohio, United States
  • Oregon
    Portland, Oregon, United States
  • Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Rhode Island
    Providence, Rhode Island, United States
  • South Carlonia
    Columbia, South Carolina, United States
  • Texas
    Dallas, Texas, United States
  • Texas
    Houston, Texas, United States
  • Utah
    Salt Lake City, Utah, United States
  • Virginia
    Richmond, Virginia, United States
  • Washington
    Seattle, Washington, United States
  • Edmonton
    Edmonton, Alberta, Canada
  • Vancouver
    Vancouver, British Columbia, Canada
  • Hamilton
    Hamilton, Ontario, Canada
  • Toronto
    Toronto, Ontario, Canada
  • Montreal
    Montreal, Quebec, Canada
  • Bonn
    Bonn, Germany
  • Essen
    Essen, Germany
  • Hamburg
    Hamburg, Germany
  • Munchen
    Munchen, Germany
  • Puerto Rico
    San Juan, Puerto Rico
  • Spain
    Badalona, Spain
  • Barcelona
    Barcelona, Spain
  • Madrid
    Madrid, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 8, 2011
Start
Dec 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 17, 2015
Last update
Mar 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01467479
Responsible party
Sponsor
First posted
Nov 8, 2011
Start date
Dec 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 17, 2015
Last update
Mar 17, 2015

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2a

Start the discussion